ATRC — AtriCure, Inc.

AtriCure Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $134 million, a 16% increase year-over-year.
• U.S. Revenue: $109.3 million, up 14.5% from Q3 2024.
• Adjusted EBITDA: $17.8 million, an increase of approximately $10 million compared to Q3 2024, with an adjusted EBITDA margin of 13.3%.
• Net Loss Per Share: Adjusted loss per share was $0.01, compared to $0.17 in Q3 2024.
• Cash Generation: Over $30 million in cash generated during the quarter, ending with $147.9 million in cash and investments.
• International Revenue: $25 million, up 22% year-over-year.

2. Strategic Updates and Business Highlights

• Product Launches: Successful launches of AtriClip FLEX-Mini, cryoSPHERE MAX, and cryoXT, contributing to growth in appendage management and pain management segments.
• Clinical Trials: Enrollment completion in the LeAAPS trial with over 6,500 patients, focusing on stroke prevention in cardiac surgery patients without prior Afib diagnosis. Initiation of the BoxX-NoAF trial aimed at reducing postoperative Afib.
• Appendage Management Growth: Worldwide revenue grew over 20%, driven by AtriClip products.
• Open Ablation Growth: Increased over 18%, with significant contributions from the EnCompass Clamp.
• Pain Management Growth: Grew 28%, driven by cryoSPHERE product innovations.

3. Forward Guidance and Outlook

• Full Year 2025 Revenue Guidance: Expected to be between $532 million and $534 million, reflecting 14% to 15% growth compared to 2024.
• Adjusted EBITDA Guidance: Raised to approximately $55 million to $57 million for the full year 2025.
• Gross Margin: Expected to be slightly higher than 2024, with ongoing improvements from product mix and manufacturing efficiencies.

4. Bad News, Challenges, or Points of Concern

• Minimally Invasive Ablation Sales: Experienced a decline to $7.4 million, indicating challenges in that segment.
• Market Dynamics: The minimally invasive hybrid therapy market remains challenging due to increased adoption of PFA catheter technology.
• Competitive Pressures: Concerns about future entrants in the appendage management space, although management views competition as a validation of the market.

5. Notable Q&A Insights

• Impact of CMS Proposal: Management expressed that changes in the ASC setting might not significantly impact the EPi-Sense business, with growth expected from non-responders to PFA treatments.
• Japan Market Opportunity: Approximately 40,000 cardiac surgeries annually, with expectations for gradual market penetration following recent product approvals.
• Sustainability of Open Ablation Growth: Growth driven by increased surgeon adoption and awareness, particularly in CABG patients, with significant room for market penetration.
• Hybrid Business Recovery: Management anticipates a gradual recovery in hybrid procedures as more patients fail catheter ablations and seek alternative treatments.
• CryoXT Launch: Currently in a focused launch phase, with expectations for significant contributions to revenue in 2026.

This summary encapsulates the key financial metrics, strategic initiatives, future outlook, challenges faced, and insights from the Q&A session, providing a comprehensive overview of AtriCure's performance and strategic direction for Q3 2025.